BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...Nordisk A/S (CSE:NOVO B; NYSE:NVO) Ziylo Ltd. 8/17/18 ND ND $800 Astellas Pharma Inc. (Tokyo:4503) Quethera Ltd....
BioCentury | Aug 17, 2018
Company News

Astellas acquires ophthalmic company Quethera

...Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85...
...cell model of neurological damage compared with empty vector. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Quethera Ltd....
BioCentury | Aug 10, 2018
Company News

Astellas acquires ophthalmic company Quethera

...Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85...
...Midven's Rainbow Seed Fund. Allison Johnson Astellas Pharma Inc. Brain-derived neurotrophic factor (BDNF) Neurotrophic tyrosine kinase receptor 2 (TrkB) (NTRK2) Quethera Ltd....
Items per page:
1 - 3 of 3
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...Nordisk A/S (CSE:NOVO B; NYSE:NVO) Ziylo Ltd. 8/17/18 ND ND $800 Astellas Pharma Inc. (Tokyo:4503) Quethera Ltd....
BioCentury | Aug 17, 2018
Company News

Astellas acquires ophthalmic company Quethera

...Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85...
...cell model of neurological damage compared with empty vector. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Quethera Ltd....
BioCentury | Aug 10, 2018
Company News

Astellas acquires ophthalmic company Quethera

...Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85...
...Midven's Rainbow Seed Fund. Allison Johnson Astellas Pharma Inc. Brain-derived neurotrophic factor (BDNF) Neurotrophic tyrosine kinase receptor 2 (TrkB) (NTRK2) Quethera Ltd....
Items per page:
1 - 3 of 3